Semaglutide, the drug found in Ozempic and Wegovy, was linked to nearly 40% fewer asthma attacks in a large real-world study. Researchers say GLP-1 drugs may offer respiratory benefits to their effects on diabetes and obesity, but clinical trials are needed to confirm the findings.
Semaglutide, the drug found in Ozempic and Wegovy, was linked to nearly 40% fewer asthma attacks in a large real-world study.
Researchers say GLP-1 drugs may offer respiratory benefits to their effects on diabetes and obesity, but clinical trials are needed to confirm the findings.
It was also associated with about 20% fewer COPD flare-ups.
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
Semaglutide, the drug found in Ozempic and Wegovy, was linked to nearly 40% fewer asthma attacks in a large real-world study. Researchers say GLP-1 drugs may offer respiratory benefits to their effects on diabetes and obesity, but clinical trials are needed to confirm the findings. It was also associated with about 20% fewer COPD flare-ups.
It was also associated with about 20% fewer COPD flare-ups.
Open the app view to save this story, compare related coverage, and continue from the same source.